ReviewFrontiers in immunology2023
The central role of natural killer cells in preeclampsia.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 39 citations in OpenAlex.
- Therapeutics Beyond Delivery: Repurposed Drugs and Biologic Pathways.Current hypertension reports · 2026Review
- The Immunopathology of Preeclampsia.Biomedicines · 2026Review
- Understanding Preeclampsia: Integrating Placental Dysfunction, Immune Dysregulation and microRNA-Mediated Epigenetic Regulation.International journal of molecular sciences · 2026Review
- Transcriptional Profile Change of NK-92 Cells in Presence of Cytokines, TGFβ Signaling Pathway Inhibitor and CDK7/12/13 Kinase Inhibitor.International journal of molecular sciences · 2026Article
- Revealing an enhanced cytotoxic immune microenvironment at the human maternal-fetal interface in preeclampsia.Cell biology and toxicology · 2026Article
- Single-cell insights into trophoblast heterogeneity and adaptive dysfunction in selective fetal growth restriction.Communications biology · 2026Article
- Identifying mitochondrial genes and potential biological functions in pre-eclampsia: bioinformatics and experimental insights.Frontiers in genetics · 2026Article
- The neuro-immune axis in preeclampsia: from the maternal-fetal interface to systemic dysregulation.Frontiers in immunology · 2026Review
- Single-cell RNA sequencing of leukocytes at the maternal-fetal interface in physiological and pathological Nodal-deficient pregnancies.Frontiers in immunology · 2026Article
- Immune Cells in Preeclampsia.International journal of molecular sciences · 2025Review
- Molecular Insights into Human Placentation: From Villous Morphogenesis to Pathological Pathways and Translational Biomarkers.International journal of molecular sciences · 2025Review
- Exploring the Vertical Transmission of Exosomes in Diagnostic and Therapeutic Targets for Pregnancy Complications.ACS biomaterials science & engineering · 2025Review
- Systemic and Local Immunological Markers in Preeclampsia.Diagnostics (Basel, Switzerland) · 2025Article
- Research trajectory of the mechanism of preeclampsia: a scientometric perspective.Journal of health, population, and nutrition · 2025Article
- Prevention of Pre-Eclampsia: Modern Strategies and the Role of Early Screening.Journal of clinical medicine · 2025Review
- Integrated analysis of DNA methylation and transcriptome profiles to identify oxidative stress-related placenta-specific molecules for preeclampsia.The journal of obstetrics and gynaecology research · 2025Article
- NK cell dysfunction in antiphospholipid syndrome.Frontiers in immunology · 2025Review
- Folic acid supplementation on congenital heart disease and its dual character.Current research in pharmacology and drug discovery · 2025Review
- Alloimmune Causes of Recurrent Pregnancy Loss: Cellular Mechanisms and Overview of Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2024Review
- Circulating Immune Cells from Early- and Late-onset Pre-eclampsia Displays Distinct Profiles with Differential Impact on Endothelial Activation.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia (PE) is a disease that is unique to pregnancy and affects multiple systems. It can lead to maternal and perinatal mortality. The precise etiology of PE is unclear. Patients with PE may have systemic or local immune abnormalities. A group of researchers has proposed that the immune communication between the fetus and mother is primarily moderated by natural killer (NK) cells as opposed to T cells, since NK cells are the most abundant immune cells in the uterus. This review examines the immunological roles of NK cells in the pathogenesis of PE. Our aim is to provide obstetricians with a comprehensive and updated research progress report on NK cells in PE patients. It has been reported that decidual NK (dNK) cells contribute to the process of uterine spiral artery remodeling and can modulate trophoblast invasion. Additionally, dNK cells can stimulate fetal growth and regulate delivery. It appears that the count or proportion of circulating NK cells is elevated in patients with or at risk for PE. Changes in the number or function of dNK cells may be the cause of PE. The Th1/Th2 equilibrium in PE has gradually shifted to an NK1/NK2 equilibrium based on cytokine production. An improper combination of killer cell immunoglobulin-like receptor (KIR) and human leukocyte antigen (HLA)-C may lead to insufficient activation of dNK cells, thereby causing PE. In the etiology of PE, NK cells appear to exert a central effect in both peripheral blood and the maternal-fetal interface. To maintain immune equilibrium both locally and systemically, it is necessary to take therapeutic measures directed at NK cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.